How Insurance Benefit Design Uses Generics to Cut Costs

Did you know that generic drugs make up over 91% of prescriptions filled in the United States, yet they account for only about 22% of total drug spending? That massive gap is not an accident. It is the result of deliberate insurance benefit design, which uses strategic financial structures and rules to steer patients toward lower-cost medications. For years, health insurers and Pharmacy Benefit Managers (PBMs), intermediaries that negotiate drug prices between insurers, pharmacies, and manufacturers have built systems specifically designed to maximize the use of generics. But how exactly do these plans work, and who really benefits from them?

The foundation of this strategy lies in the Hatch-Waxman Act, a 1984 U.S. law that streamlined the approval process for generic drugs by allowing them to prove bioequivalence rather than repeating clinical trials. This legislation allowed cheaper alternatives to enter the market once brand-name patents expired. Since then, insurance companies have refined their tools to ensure you pick up the generic bottle instead of the brand-name one. The result? According to the IQVIA Institute, generic drugs saved the U.S. healthcare system approximately $3.7 trillion between 2013 and 2022. However, the system is complex, and while it saves billions, some argue that opaque pricing practices prevent patients from seeing the full savings at the pharmacy counter.

The Mechanics of Tiered Formularies

The most visible tool in an insurer’s arsenal is the formulary. Think of a formulary as a ranked list of approved drugs. Insurers group these drugs into tiers based on cost and preferred status. You likely see this when you fill a prescription or check your plan details online.

• Tier 1 (Preferred Generics): These are the cheapest options. Copayments often range from $0 to $10 for a 30-day supply. This tier includes almost all FDA-approved generic equivalents.
• Tier 2 (Preferred Brands): Brand-name drugs that the insurer has negotiated good rates for. Copays here might jump to $25-$50.
• Tier 3 (Non-Preferred Brands): Expensive brand names with little competition. Copays can exceed $60 or even $100.

This structure creates a powerful financial incentive. If your brand-name medication costs $50 out-of-pocket but the generic version costs $5, the math is simple for most people. Data from the Kaiser Family Foundation shows that commercial plans consistently use this tiered approach to drive utilization toward Tier 1. In fact, 98.7% of commercial health plans used tiered formularies prioritizing generics as of 2024. By making the generic option significantly cheaper at the point of sale, insurers reduce their overall liability without necessarily denying coverage for the brand-name drug entirely.

Mandatory Substitution and Step Therapy

Price differences alone aren’t always enough to change behavior, especially when patients feel strongly attached to a specific brand. To bridge this gap, benefit designs employ more rigid controls. One of the most common is mandatory generic substitution. In 49 states, pharmacists are legally permitted-and often required-to substitute a generic drug for a brand-name one unless the prescriber explicitly writes “Dispense as Written” on the prescription. This automatic switch happens millions of times daily, ensuring that the lowest-cost option is dispensed by default.

Another mechanism is step therapy, also known as “fail-first” protocols. Under this rule, an insurer will only cover a more expensive brand-name drug if you first try and fail on a cheaper generic alternative. As of 2023, 92% of Medicare Part D plans utilized step therapy protocols. For example, if you need a new statin for cholesterol, your plan might require you to take generic atorvastatin first. Only if you experience side effects or insufficient results would they approve coverage for a newer, branded statin. While this can delay access to preferred treatments, it forces a trial of the cost-effective option first, significantly lowering aggregate spending for the insurer.

The PBM Profit Paradox

While insurers save money, the journey of those savings is not always straightforward. Enter the Pharmacy Benefit Manager (PBM). Companies like CVS Caremark, OptumRx, and Express Scripts process the vast majority of prescription claims. They negotiate rebates from drug manufacturers and pass some of those savings back to health plans. However, critics argue that the system is opaque.

A 2022 white paper from the USC Schaeffer Center highlighted a troubling trend: spread pricing. This occurs when a PBM charges an insurer more for a generic drug than it pays the pharmacy. The difference stays in the PBM’s pocket. Consequently, while the insurer sees lower aggregate costs due to high generic volume, the individual patient might still face higher-than-expected copays. Some research suggests patients could be overpaying by $10 to $15 per prescription due to these hidden margins. This disconnect explains why some consumers feel frustrated despite being steered toward “cheaper” generics.

Impact on Different Insurance Models

Not all insurance programs handle generics the same way. Medicare Part D, which covers over 50 million beneficiaries, uses standardized benefit designs with mandatory generic tiers. However, out-of-pocket costs vary wildly depending on the specific plan chosen. In contrast, Medicaid programs operate under federal Upper Payment Limits (UPL), capping reimbursement for generics at 250% of the average manufacturer price. This strict cap helps Medicaid achieve slightly higher generic dispensing rates (89.3% in 2022) compared to the commercial market (87.1%).

Self-insured employers are also aggressive in their cost-cutting. A study from Johns Hopkins University found that large self-insured employers achieved savings of 9% to 15% by substituting prescription drugs with therapeutically equivalent lower-cost options. Meanwhile, new direct-to-consumer models like the Mark Cuban Cost Plus Drug Company challenge traditional PBMs by offering transparent cost-plus pricing. An economic evaluation showed that uninsured patients could save a median of $4.96 per prescription by bypassing insurance for certain generics, highlighting the potential inefficiencies in the current insured model.

Navigating Your Benefits as a Patient

Understanding these mechanisms empowers you to manage your healthcare costs better. Here is what you should look for in your plan:

1. Check the Formulary Tier: Before starting a new medication, ask your doctor if a generic equivalent exists and which tier it falls under in your plan.
2. Understand Step Therapy: If your claim is denied due to step therapy, ask your provider if they can submit a “peer-to-peer” review to justify the brand name, or be prepared to try the generic first.
3. Watch for Copay Cliffs: With the introduction of coinsurance (paying a percentage rather than a flat fee) for some plans, calculate whether the generic’s lower base price actually results in a lower out-of-pocket cost for you.
4. Leverage Transparency Tools: Use apps and websites that show cash prices versus insured prices. Sometimes, paying cash for a generic at a discount pharmacy can be cheaper than your copay, especially if your deductible hasn’t been met.

The shift toward generic-focused benefit design is irreversible. With the Inflation Reduction Act’s new drug price negotiations launching in 2026 and the CMS GENEROUS Model aiming to cut Medicaid drug spending by $40 billion over ten years, the pressure to utilize low-cost generics will only intensify. For patients, the key is staying informed about how these rules apply to your specific plan, ensuring you get the clinical care you need without falling victim to hidden costs or unnecessary delays.